NEW YORK, May 5, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of two PCT patent applications covering novel psychoplastogens, including non-hallucinogenic derivatives of DMT and ibogaine. DMT and ibogaine are both potent psychedelic…


Previous articlePsychedelic Bulletin #137: Oregon Approves First Psilocybin Service Centre; AMA Approves Psychedelic CPT Code; MindMed Seeks to Fend Off Proxy Contest
Next articlePT409 – Pathology, the DSM, and the Ontological Shock of Psychedelic Experiences